A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
Prostate Cancer
Interventions
DRUG

Degarelix

Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (40 mg/mL) at months 1, 3, 6 and 9

DRUG

Degarelix

Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 3, 6 and 9

DRUG

Degarelix

Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 4, 7 and 10

Trial Locations (56)

16801

State College Urologic Association, State College

27401

The Urology Center, Greensboro

28025

Northeast Urology Research, Concord

29572

Grand Strand Urology, Myrtle Beach

33180

South Florida Medical Research, Aventura

33901

RT Services, Inc, Fort Myers

33907

SW Florida Urological Associates, Fort Myers

35209

Urology Centers of Alabama, Homewood

35801

Medical Affiliationed Research Center, Huntsville

39202

Mississippi Urology Clinic, Jackson

64131

Kansas City Urology Care, Kansas City

65212

University of Missouri, Urology, Deptof Surgery, Columbia

71106

Regional Urology, Shreveport

76104

Urology Association of Northern Texas, Fort Worth

78229

Urology San Antonio Research, San Antonio

80012

Urology Research Option, Aurora

90505

Western Clinical Research, Torrance

91356

West Coast Clinical Research, Tarzana

91942

Center for Urological Research, La Mesa

92653

South Orange County Medical Research Center, Laguna Woods

92801

Advanced Urology Medical Center, Anaheim

98166

Seatle Urology Research Centre, Seattle

99508

Alaska Clinical Research Center, LLC, Anchorage

Unknown

UZ Gasthuisberg Leuven, Leuven

Southern Interior Medical Research Corp, Kelowna

Andreou Researce, Surrey

Can-Med Clinical Research Inc., Victoria

The Male/Female Health Centres and Research, Barrie

Brantford Urology Research, Brantford

North Bay Hospital, North Bay

The Male/Female Health Centres and Research, Oakville

The Male Health Center, Toronto

Helsinki University Hospital, Maria Hospital, Dept Urology, Helsinki

Central Hospital, North Karelian, Dept. of Urology, Joensuu

Oulu University Hospital, Department of Surgery Division of Urology, Oys

Tampere University Hospital, Dept. of Urology, Tampere

Centre Hospitalier Départemental des Oudairies, Chirurgie Urologie, La Roche-sur-Yon

Fédération d'Urologie et Néphrologie, Nice

Gemeinschaftspraxis Dres Effert und Benedic, Aachen

Klinik fuer Urologie, Vivantes Klinikum Am Urban, Berlin

Academic Medical Center, Urology, Amsterdam

St. Elisabeth Hospital, Tilburg

Centrul Medical Privat, Arad

"Clinical Hospital Prof. Dr. Theodor Burghele, Urology Department", Bucharest

University CF Hospital No.2, Urology Clinic, Bucharest

Andros Clinic, Saint Petersburg

City Hospital #15, Saint Petersburg

City Hospital #26, Saint Petersburg

Pavlov State Medical University, Outpatient Diagnostic Center affiliated with the Urology Department, Saint Petersburg

Pavlov State Medical University, Urology Department, Saint Petersburg

Clinical Center of Serbia Institute of Urology and Nephrology, Belgrade

Clinical Center Novi Sad, Clinic of Urology Hajduk, Novi Sad

Ward 10, NHS Forth Valley Acute Operating Division, Falkirk and District Royal Infirmary, Falkirk

Mount Vernon Cancer Centre, Marie Curie Research Wing, Middlesex

Castle Hill Hospital, Dept. Urology, North Humberside

Level 7, Urology Research Unit, Derriford Hospital, Plymouth

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY

NCT00116753 - A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter